Main Street Financial Solutions, LLC Vertex Pharmaceuticals Inc Transaction History

Main Street Financial Solutions, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$392.81 - $485.53 $149,660 - $184,986	381 Added 16.44%	2,699 $1.27 Million
Q1 2024 Apr 22, 2024	BUY	$407.69 - $446.08 $945,025 - $1.03 Million	2,318 New	2,318 $968,000
Q3 2023 Nov 02, 2023	BUY	$338.18 - $362.46 $3,719 - $3,987	11 Added 1.88%	596 $207,000
Q2 2023 Aug 04, 2023	BUY	$314.42 - $351.91 $183,935 - $205,867	585 New	585 $205,000
Q2 2022 Jul 27, 2022	SELL	$234.96 - $292.55 $867,237 - $1.08 Million	-3,691 Closed	0 $0
Q1 2022 Apr 22, 2022	BUY	$221.42 - $260.97 $14,170 - $16,702	64 Added 1.76%	3,691 $963,000
Q4 2021 Feb 08, 2022	BUY	$177.01 - $223.45 $286,048 - $361,095	1,616 Added 80.36%	3,627 $796,000
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $19,045 - $21,313	105 Added 5.51%	2,011 $365,000
Q2 2021 Aug 10, 2021	BUY	$187.49 - $221.1 $124,868 - $147,252	666 Added 53.71%	1,906 $384,000
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $56,723 - $66,118	-274 Reduced 18.1%	1,240 $266,000
Q4 2020 Mar 01, 2021	BUY	$207.01 - $276.09 $313,413 - $418,000	1,514 New	1,514 $358,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Main Street Financial Solutions, LLC, based on Form 13F filings with the SEC.

Stay updated on Main Street Financial Solutions, LLC with notifications on news.